Multicenter, Randomized, Open Label, Parallel Study to Evaluate the Efficacy & Safety of IVF-M HP Inj. vs. Menopur® Inj.

Inclusion Criteria: * Adult women from 20 through 39 years of age at the screening * Subjects with the mean menstrual cycle day (MCD) of 25 to 35 days * Subjects with the Follicle Stimulating Hormone (FSH) concentration at the screening not exceeding the upper limit of the normal range (ULN) * Those diagnosed with infertility due to at least one of the following causes of infertility * Fallopian tubal factor * Infertility due to unknown cause * Male infertility * Complex factor * Subjects with the normal ovarian and uterine function * Subjects with not more than 3 times of the prior experience of in vitro fertilization * Subjects who had neither administered clomiphene citrate within 30 days nor gonadotropin within 14 days of the IP administration day * Subjects who were informed on the objective, method and effect etc. of the clinical study and signed the informed consent form Exclusion Criteria: * Subjects contraindicated to pregnancy * Subjects with BMI \> 30 (BMI; kg/m2) * Subjects diagnosed with polycystic ovary syndrome (PCOS) * Subjects who had experienced previously at least Grade 4 ovarian hyperstimulation syndrome (OHSS) * Subjects with poor response to gonadotropin (According to the Bologna criteria\* below) \*At least two of the following three features must be present: ① Advanced maternal age (\>=40 years) or any other risk factor for Poor Ovarian Response (POR) ② A previous POR (\<=3 oocyte with a conventional stimulation protocol) ③ An abno…